Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER) - 04/03/14
, Thomas Bachelot, MD e, Frederic Commo, MSc b, Mario Campone, ProfMD f, Monica Arnedos, MD a, b, Véronique Dieras, MD g, Magali Lacroix-Triki, MD i, Ludovic Lacroix, PharmPhD c, Pascale Cohen, PhD j, k, l, David Gentien, MSc h, Jose Adélaide, PhD m, Florence Dalenc, MD o, Anthony Goncalves, MD n, Christelle Levy, MD q, Jean-Marc Ferrero, ProfMD r, Jacques Bonneterre, ProfMD s, Claudia Lefeuvre, MD t, Marta Jimenez, MSc u, Thomas Filleron, PhD p, Hervé Bonnefoi, ProfMD vSummary |
Background |
Breast cancer is characterised by genomic alterations. We did a multicentre molecular screening study to identify abnormalities in individual patients with the aim of providing targeted therapy matched to individuals’ genomic alterations.
Methods |
From June 16, 2011, to July 30, 2012, we recruited patients who had breast cancer with a metastasis accessible for biopsy in 18 centres in France. Comparative genomic hybridisation (CGH) array and Sanger sequencing on PIK3CA (exon 10 and 21) and AKT1 (exon 4) were used to assess metastatic biopsy samples in five centres. Therapeutic targets were decided on the basis of identified genomic alterations. The primary objective was to include 30% of patients in clinical trials testing a targeted therapy and, therefore, the primary outcome was the proportion of patients to whom a targeted therapy could be offered. For the primary endpoint, the analyses were done on the overall population registered for the trial. This trial is registered with ClinicalTrials.gov, number NCT01414933.
Findings |
423 patients were included, and biopsy samples were obtained from 407 (metastatic breast cancer was not found in four). CGH array and Sanger sequencing were feasible in 283 (67%) and 297 (70%) patients, respectively. A targetable genomic alteration was identified in 195 (46%) patients, most frequently in PIK3CA (74 [25%] of 297 identified genomic alterations), CCND1 (53 [19%]), and FGFR1 (36 [13%]). 117 (39%) of 297 patients with genomic tests available presented with rare genomic alterations (defined as occurring in less than 5% of the general population), including AKT1 mutations, and EGFR, MDM2, FGFR2, AKT2, IGF1R, and MET high-level amplifications. Therapy could be personalised in 55 (13%) of 423 patients. Of the 43 patients who were assessable and received targeted therapy, four (9%) had an objective response, and nine others (21%) had stable disease for more than 16 weeks. Serious (grade 3 or higher) adverse events related to biopsy were reported in four (1%) of enrolled patients, including pneumothorax (grade 3, one patient), pain (grade 3, one patient), haematoma (grade 3, one patient), and haemorrhagic shock (grade 3, one patient).
Interpretation |
Personalisation of medicine for metastatic breast cancer is feasible, including for rare genomic alterations.
Funding |
French National Cancer Institute, Breast Cancer Research Foundation, Odyssea, Operation Parrains Chercheurs.
Le texte complet de cet article est disponible en PDF.Plan
Vol 15 - N° 3
P. 267-274 - mars 2014 Retour au numéro
Article précédent
- Beauty and the Breast
- Talha Khan Burki
- Ionising radiation-free whole-body MRI versus 18F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study
- Christopher Klenk, Rakhee Gawande, Lebriz Uslu, Aman Khurana, Deqiang Qiu, Andrew Quon, Jessica Donig, Jarrett Rosenberg, Sandra Luna-Fineman, Michael Moseley, Heike E Daldrup-Link
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?